024 TLCS Symposium

In recent years, immune checkpoint inhibitors have gradually begun to play an important role in the neoadjuvant and adjuvant treatment of early-stage lung cancer.

Through this symposium, we would like to explore the current development and role of immunotherapy in early-stage lung cancer, how it changes the current clinical practice, and incorporate the perspective of surgeon as well for the discussing the consideration of adding immunotherapy in to neoadjuvant or adjuvant treatment from different specialties.